Outcomes of Real-World Integrated HCV Microelimination for People Who Inject Drugs: An expansion of the Punjab Model.

BACKGROUND: The prevalence of chronic hepatitis C (CHC) in People Who Inject Drugs (PWID) is 8-10% as compared to 3·6% in the general population in Punjab, India. We assessed the real-world efficacy and safety of free-of-charge generic direct-acting antivirals (DAAs), sofosbuvir with an NS5A inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhiman, Radha K., Grover, Gagandeep S., Premkumar, Madhumita, Roy, Akash, Taneja, Sunil, Duseja, Ajay, Arora, Sanjeev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529203/
https://www.ncbi.nlm.nih.gov/pubmed/34712928
http://dx.doi.org/10.1016/j.eclinm.2021.101148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529203/
https://www.ncbi.nlm.nih.gov/pubmed/34712928
http://dx.doi.org/10.1016/j.eclinm.2021.101148

Ejemplares similares